慢性疲労症候群治療法の世界市場2019-2023

【英語タイトル】Chronic Fatigue Syndrome Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Technavioが出版した調査資料(IRTNTR31884)・商品コード:IRTNTR31884
・発行会社(調査会社):Technavio
・発行日:2019年8月28日
・ページ数:127
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Technavio社の本調査レポートでは、慢性疲労症候群治療法の世界市場について調べ、慢性疲労症候群治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、慢性疲労症候群治療法の市場規模をセグメンテーション別(製品別(鎮痛剤及びNSAID、抗うつ薬及び抗精神病薬、抗菌薬及び免疫調節薬)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は慢性疲労症候群治療法の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・慢性疲労症候群治療法の市場状況
・慢性疲労症候群治療法の市場規模
・慢性疲労症候群治療法の市場予測
・慢性疲労症候群治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(鎮痛剤及びNSAID、抗うつ薬及び抗精神病薬、抗菌薬及び免疫調節薬)
・慢性疲労症候群治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Chronic Fatigue Syndrome Therapeutics Market: About this market
Technavio’s chronic fatigue syndrome (CGS) therapeutics market analysis considers sales from pain relievers and NSAIDs, antidepressant and antipsychotic drugs, and antimicrobial and immunomodulatory drugs. Our analysis also considers the sales of chronic fatigue syndrome therapeutics in Asia, Europe, North America, and ROW. In 2018, the pain relievers and NSAIDs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as relieving patients from pain and reducing inflammation will play a significant role in the pain relievers and NSAIDs segment to maintain its market position. Also, our global chronic fatigue syndrome therapeutics market report looks at factors such as increasing use of off-label pharmacological treatment for CFS, increasing risk factors of CFS, and initiatives to increase awareness about CFS. However, lack of specific diagnostic tests for confirmation of CFS, lack of approved drugs for the treatment of CFS, and complex pathogenesis of CFS may hamper the growth of the chronic fatigue syndrome therapeutics industry over the forecast period.

Global Chronic Fatigue Syndrome Therapeutics Market: Overview

Increasing risk factors of CFS
Some theories indicate that viral infection, psychological stress, genetic factors increase the risk of CFS. The prevalence of CFS is four times more in women than in men. Chronic physical or emotional stress also may result in CFS. Stress affects the hypothalamic-pituitary-adrenal axis, which is a complex network that controls the body’s reaction, such as immune response, digestion, energy usage, and mood. The prevalence of stress is increasing globally due to many societal factors and work-related pressure which is increasing the risk factors of CFS. These risk factors of CFS will lead to the expansion of the global chronic fatigue syndrome therapeutics market at a CAGR of over 4% during the forecast period.

R&D of new drugs for the treatment of CFS
The lack of approved and effective drugs has led the vendors to focus on the R&D of novel drugs to cater to the unmet need in CFS pharmacological therapy. Researchers at Stanford University School of Medicine are harnessing the nanoelectronics-based diagnostic test, developed by them, to screen for drug-based treatments. These treatments are screened by adding controlled doses of several different potentially therapeutic drugs to the patient’s blood samples and performing diagnostic tests. The research funding for CFS has increased over the last couple of years. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global chronic fatigue syndrome therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global chronic fatigue syndrome therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic fatigue syndrome therapeutics manufacturers, that include Hemispherx Biopharma Inc., Lupin Ltd., Mylan NV, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the chronic fatigue syndrome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Pain relievers and NSAIDs – Market size and forecast 2018-2023
• Antidepressant and antipsychotic drugs -
• Market size and forecast 2018-2023
• Antimicrobial and immunomodulatory drugs –
• Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Development of new diagnostic tests for CFS
• R&D of new drugs for the treatment of CFS
• Increasing focus on investigation
• Role of immune system in CFS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Hemispherx Biopharma, Inc.
• Lupin Ltd.
• Mylan NV
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Pain relievers and NSAIDs – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Pain relievers and NSAIDs – Year-over-year growth 2019-2023 (%)
Exhibit 22: Antidepressant and antipsychotic drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antidepressant and antipsychotic drugs – Year-over-year growth 2019-2023 (%)
Exhibit 24: Antimicrobial and immunomodulatory drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antimicrobial and immunomodulatory drugs – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Hemispherx Biopharma Inc. – Vendor overview
Exhibit 47: Hemispherx Biopharma Inc. – Business segments
Exhibit 48: Hemispherx Biopharma Inc. – Organizational developments
Exhibit 49: Hemispherx Biopharma Inc. – Key offerings
Exhibit 50: Lupin Ltd. – Vendor overview
Exhibit 51: Lupin Ltd. – Business segments
Exhibit 52: Lupin Ltd. – Organizational developments
Exhibit 53: Lupin Ltd. – Geographic focus
Exhibit 54: Lupin Ltd. – Key offerings
Exhibit 55: Mylan NV – Vendor overview
Exhibit 56: Mylan NV – Product segments
Exhibit 57: Mylan NV – Organizational developments
Exhibit 58: Mylan NV – Geographic focus
Exhibit 59: Mylan NV – Segment focus
Exhibit 60: Mylan NV – Key offerings
Exhibit 61: Pfizer Inc. – Vendor overview
Exhibit 62: Pfizer Inc. – Business segments
Exhibit 63: Pfizer Inc. – Organizational developments
Exhibit 64: Pfizer Inc. – Geographic focus
Exhibit 65: Pfizer Inc. – Segment focus
Exhibit 66: Pfizer Inc. – Key offerings
Exhibit 67: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 68: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 69: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 70: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 71: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: Definition of market positioning of vendors



【掲載企業】

Hemispherx Biopharma Inc., Lupin Ltd., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

★調査レポート[慢性疲労症候群治療法の世界市場2019-2023] (コード:IRTNTR31884)販売に関する免責事項を必ずご確認ください。
★調査レポート[慢性疲労症候群治療法の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆